ES2084965T3 - Composicion farmaceutica estabilizada de il-2 recombinante humana no glicosilada, en forma reducida y su procedimiento de preparacion. - Google Patents

Composicion farmaceutica estabilizada de il-2 recombinante humana no glicosilada, en forma reducida y su procedimiento de preparacion.

Info

Publication number
ES2084965T3
ES2084965T3 ES92403362T ES92403362T ES2084965T3 ES 2084965 T3 ES2084965 T3 ES 2084965T3 ES 92403362 T ES92403362 T ES 92403362T ES 92403362 T ES92403362 T ES 92403362T ES 2084965 T3 ES2084965 T3 ES 2084965T3
Authority
ES
Spain
Prior art keywords
glycosilated
reduced form
pharmaceutical composition
preparation procedure
human non
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92403362T
Other languages
English (en)
Inventor
Bruno Maneglier
Bernard Voncken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Application granted granted Critical
Publication of ES2084965T3 publication Critical patent/ES2084965T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA ESTABILIZADA DE IL2 RECOMBINANTE HUMANA NO GLICOLISADA EN FORMA REDUCIDA QUE COMPRENDE ACIDO CITRICO, MANITROL, DEXTRANO Y EDTA CALCICO, A SU PROCESO DE PREPARACION ASI COMO A LA UTILIZACION DEL DEXTRANO Y DEL EDTA CALCICO PARA LA ESTABILIZACION DE LAS COMPOSICIONES FARMACEUTICAS.
ES92403362T 1991-12-12 1992-12-11 Composicion farmaceutica estabilizada de il-2 recombinante humana no glicosilada, en forma reducida y su procedimiento de preparacion. Expired - Lifetime ES2084965T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9115418A FR2684878B1 (fr) 1991-12-12 1991-12-12 Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.

Publications (1)

Publication Number Publication Date
ES2084965T3 true ES2084965T3 (es) 1996-05-16

Family

ID=9419958

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92403362T Expired - Lifetime ES2084965T3 (es) 1991-12-12 1992-12-11 Composicion farmaceutica estabilizada de il-2 recombinante humana no glicosilada, en forma reducida y su procedimiento de preparacion.

Country Status (18)

Country Link
US (1) US5340574A (es)
EP (1) EP0554634B1 (es)
JP (1) JP3291340B2 (es)
KR (1) KR930012023A (es)
AT (1) ATE135917T1 (es)
AU (1) AU662940B2 (es)
CA (1) CA2085142A1 (es)
DE (1) DE69209486T2 (es)
DK (1) DK0554634T3 (es)
ES (1) ES2084965T3 (es)
FR (1) FR2684878B1 (es)
GR (1) GR3019440T3 (es)
HU (1) HU218103B (es)
IL (1) IL103862A (es)
MX (1) MX9207199A (es)
RU (1) RU2107511C1 (es)
UA (1) UA26898C2 (es)
ZA (1) ZA929627B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018119A1 (en) * 1997-10-03 1999-04-15 Shionogi & Co., Ltd. Process for freeze-drying proteins
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
CZ20021186A3 (cs) * 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
RU2169004C1 (ru) * 1999-11-23 2001-06-20 Государственный научно-исследовательский институт особо чистых биопрепаратов Ранозаживляющая композиция
DE602004019761D1 (de) 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
JP2008501639A (ja) * 2004-04-23 2008-01-24 ノベシン リミテッド タンパク質を安定化、保護及び可溶化させるための方法及びキット
MX2007015039A (es) * 2005-06-06 2008-01-24 Novo Nordisk As Composiciones de il-21 estabilizadas.
SG10201502398RA (en) * 2010-04-27 2015-05-28 Scil Technology Gmbh Stable MIA/CD-RAP formulations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251001C (es) *
FR353150A (fr) * 1905-04-08 1905-09-04 Gerardo Caffaro Compteurs à gaz
FR452598A (fr) * 1912-12-26 1913-05-19 Lanston Monotype Corp Ltd Perfectionnements apportés aux machines servant à la composition typographique
JPS61500790A (ja) * 1984-03-28 1986-04-24 シタス　コ−ポレイシヨン 微生物的に製造されたインターロイキン―２を含有する組成物
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5204094A (en) * 1991-01-17 1993-04-20 Roussel Uclaf Treatment of pneumothorax

Also Published As

Publication number Publication date
IL103862A (en) 1997-02-18
MX9207199A (es) 1993-07-01
RU2107511C1 (ru) 1998-03-27
AU3004192A (en) 1993-06-17
JPH05345728A (ja) 1993-12-27
DK0554634T3 (da) 1996-07-01
DE69209486D1 (de) 1996-05-02
US5340574A (en) 1994-08-23
CA2085142A1 (fr) 1993-06-13
ATE135917T1 (de) 1996-04-15
GR3019440T3 (en) 1996-06-30
FR2684878A1 (fr) 1993-06-18
DE69209486T2 (de) 1996-09-12
JP3291340B2 (ja) 2002-06-10
HU9203925D0 (en) 1993-03-29
AU662940B2 (en) 1995-09-21
HU218103B (hu) 2000-06-28
EP0554634B1 (fr) 1996-03-27
FR2684878B1 (fr) 1994-02-11
HUT63575A (en) 1993-09-28
ZA929627B (en) 1993-12-13
IL103862A0 (en) 1993-04-04
KR930012023A (ko) 1993-07-20
EP0554634A1 (fr) 1993-08-11
UA26898C2 (uk) 1999-12-29

Similar Documents

Publication Publication Date Title
ES2013394A6 (es) Procedimiento para preparar una composicion farmaceutica de relaxina humana biologicamente activa.
IL74804A0 (en) Human physiologically active polypeptide,its production and pharmaceutical compositions containing it
NZ228754A (en) Vitamin d analogues and pharmaceutical compositions
HU9302366D0 (en) Conjugates of interferons and method for producing them
FI943563L (fi) Uusia biologisesti aktiivisia polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
DK395689A (da) Pharmaceutisk tilberedning til behandling af diabetes mellitus
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
FI916077A7 (fi) Glykosyloimattomia ihmisen interleukiini 3:n proteiinianalogeja
ES2084965T3 (es) Composicion farmaceutica estabilizada de il-2 recombinante humana no glicosilada, en forma reducida y su procedimiento de preparacion.
MX9203175A (es) Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion.
UA27055C2 (uk) Лікарський препарат імуhозаміhhої дії hа осhові клітиhhої суспеhзії та спосіб лікуваhhя сиhдрому hабутого імуhодефіциту (віл-іhфекції) з використаhhям цього препарату
NO863027D0 (no) Peptidpreparater med kontinuerlig avgivelse.
IL89816A0 (en) Synergistically active veterinary compositions and their preparation
IL88934A0 (en) Recombinant human interleukin-1alpha polypeptides,their preparation and pharmaceutical compositions containing them
SE8403659D0 (sv) Synergistic pharmaceutical composition
KR900701299A (ko) Cpf 펩티드 조성물 및 이를 사용하는 방법
FI930967A7 (fi) Substituoituja 6,7-dihydroimidatso(1,5,4-ef)(1,5)bentsodiatsepin-6-one ja, niiden valmistus ja farmaseuttiset koostumukset
DE69004051D1 (de) Verwendung eines Polypeptides mit Gammainterferon-Aktivität zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von primitivem Pleura-Krebs.
IL74760A0 (en) Human physiologically active polypeptide,its production and pharmaceutical compositions containing it
MX9201735A (es) Composicion farmaceutica para el tratamiento y profilaxis de inflamacion y dolor en mamiferos.
LV5733A4 (lv) Ranitidina un bistuma ar karbonskabem kompleksa sali un to farmaceitiskas kompozicijas
ITMI913398A1 (it) Derivati dell'eserolina ad attivita' anticolinesterasica procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
IT1255269B (it) Composizione farmaceutica avente attivita' antivirale
MX9101804A (es) Composicion para preparaciones farmaceuticas solidas con vitaminas de activas y procedimiento para la preparacion de las mismas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 554634

Country of ref document: ES